

The divergence of mortality curves is notable beyond follow-up duration of 1 year – the time where most of the LAAC arm discontinued anticoagulant therapy. It is noteworthy in the PRAGUE-17 trial, the LAAC group did not require anticoagulation (only 13.8% of the patients received apixaban for 3 months).³ This observation might indeed favor lower bleeding in the device arm, and therefore conferred a lower mortality.

The nonstatistically significant trend toward higher ischemic stroke or systemic embolism in the LAAC arm warrants further investigation. This observation is mainly derived from the lower-than-expected ischemic stroke events in the warfarin group of the PREVAIL trial at a rate of 0.73%. This rate could be partially explained by the relatively high appropriate time-in-therapeutic range for warfarin (68%) and/or low sample size, which is reflected by the wide confidence interval in our analysis.²

Although serious early procedure-related complications were not infrequent (5.0%) these complications occurred predominantly in earlier RCTs, with more contemporary data demonstrating a lower complication risks and higher success rates, perhaps due in part to improvements in patient selection and/or operator experience.⁴ Nevertheless, the decision of LAAC should be individualized in a shared decision-making process with appropriately selected patients, considering the short-term procedural complications, long-term thromboembolism risk absent therapy, and bleeding risks while on anticoagulation.

In conclusion, in selected patients with nonvalvular AF, LAAC is associated with lower all-cause and cardiovascular death, and nonprocedural bleeding without increased ischemic events. Further long-term adequately powered trials assessing ischemic endpoints are needed.

Disclosures

The authors have no conflicts of interest to disclose.

Babikir Kheiri, MD, MSc, MRCP^a
Kris Kumar, MD, MSc^a
Timothy F. Simpson, MD, Pharm.D^a

Mohammed Osman, MD^b
Khidir Dalouk, MD^a
Bassel Beitinjaneh, MD^a
Harsh Golwala, MD^a

Charles A. Henrikson, MD, MPH^{a,*}

^a Knight Cardiovascular Institute, Oregon Health & Science University, Portland, Oregon

^b Division of Cardiology, West Virginia University School of Medicine, Morgantown, West Virginia

1. Bungard T, Ghali W, Teo K, McAlister F, Tsuyuki R. Why do patients with atrial fibrillation not receive warfarin? *Arch Intern Med* 2000;160:41–46.
2. Reddy VY, Doshi SK, Kar S, Gibson DN, Price MJ, Huber K, Horton RP, Buchbinder M, Neuzil P, Gordon NT, Holmes DR Jr. 5-Year outcomes after left atrial appendage closure: from the PREVAIL and PROTECT AF trials. *J Am Coll Cardiol* 2017;70:2964–2975.
3. Osmancik P, Herman D, Neuzil P, Hala P, Taborsky M, Kala P, Poloczek M, Stasek J, Haman L, Branny M, Chovancik J, Cervinka P, Holy J, Kovarnik T, Zemanek D, Havranek S, Vancura V, Opatrny J, Peichl P, Tousek P, Lekesova V, Jarkovsky J, Novackova M, Benesova K, Widimsky P, Reddy VY. Left atrial appendage closure versus direct oral anticoagulants in high-risk patients with atrial fibrillation. *J Am Coll Cardiol* 2020;75:3122–3135.
4. Freeman J V, Varosy P, Price MJ, Slotwiner D, Kusumoto FM, Rammohan C, Kavinsky CJ, Turi ZG, Akar J, Koutras C, Curtis JP, Masoudi FA. The NCDR left atrial appendage occlusion registry. *J Am Coll Cardiol* 2020;75:1503–1518.

<https://doi.org/10.1016/j.amjcard.2020.07.022>

Letter to the Editor in Response to Nous et al 2020

Dear Editor,—

We were interested to read Nous et al's¹ recent article which described the prognostic benefits of using coronary computed tomography angiography (CCTA) to identify subclinical coronary artery disease (CAD) in patients with atrial fibrillation (AF). The addition of the calcium score and CCTA resulted in the re-classification of 47 patients' cardiovascular risk stratification score. Twenty-eight of these moved up in classification with 8 becoming very high-risk due to obstructive CAD. Initiation of secondary prevention (statin therapy) in these patients was concluded to be beneficial.²

Dunleavy et al³ investigated patients undergoing computed tomography of the pulmonary veins prior to AF ablation therapies. They identified 131 patients

with undiagnosed coronary artery calcification, yet none of these patients were prescribed a statin upon discharge. Thus, whilst CCTA may enhance risk stratification of AF patients it is apparent that this does not always translate to a change in clinical practice.

Nous et al¹ also states that the observed radiation dose of CCTA was high, limiting its use in asymptomatic patients. Cori et al⁴ noted that in symptomatic patients undergoing radiofrequency ablation the use of CT compared to no CT resulted in a significantly higher effective radiation dose with no improvements in clinical outcomes for AF. Whilst it is worth noting that Nous et al¹ identified benefit in stratification for cardiovascular risk, it raises the point as to whether the benefits of routine CT in all AF patients would justify the radiation exposure.

Despite these limitations, the authors introduce a novel way in which CT in AF could be of prognostic benefit.¹ As the identification and management of CAD to improve AF burden is already recommended in the international guidelines,⁵ this approach may be useful prior to catheter ablation given that patients are likely to undergo a CT. The true impact CT scans could have on stratifying the medical management of AF patients requires further investigation with larger sample sizes.

Disclosures

The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Kelly Wyatt, BSc^{a,*}

Mahmood Ahmad, MBBS^b

Ali Kirresh, MBBS^b

^a University College London Medical School, London, United Kingdom.

^b Royal Free London NHS Foundation Trust
2 July 2020

1. Nous FMA, Budde RPJ, van Dijkman ED, Musters PJ, Nieman K, Galema TW. Prognostic value of subclinical coronary artery disease in atrial fibrillation patients identified by coronary computed tomography angiography. *Am J Cardiol* 2020;126:16–22. Available at: <https://doi.org/10.1016/j.amjcard.2020.03.050>.
2. Piepoli M, Hoes A, Agewall S, Albus C, Brotons C, Catapano A, Cooney M-T, Corra U, Cosyns B, Deaton C, Graham I, Stephen Hall M, Hobbs R, Lochen M-L, Lollgen H,



- Marques-Vidal P, Perk J, Prescott E, Redon J, Richter D, Sattar N, Smulders Y, Tiberi M, Worp B Van der, de I Van, Verschuren WMM, 2016 European Guidelines on Cardiovascular Disease Prevention in Clinical Practice: The Sixth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice. Developed with the special contribution of the European Association for Cardiovascular Prevention & Rehabilitation (EACPR). *Atherosclerosis* 2016;252:207–274.
3. Dunleavy MP, Guha A, Cardona A, Fortuna C, Daoud EG, Raman SV, Harfi TT. Prevalence of coronary artery calcification on pre-atrial fibrillation ablation CT pulmonary venograms and its impact on selection for statin therapy. *J Clin Med* 2020;9:1631. <https://doi.org/10.3390/jcm9061631>.
4. Cori A Di, Zucchelli G, Faggioni L, Segreti L, Lucia R De, Barletta V, Viani S, Paperini L, Parollo M, Soldati E, Caramella D, Bongiorni MG. Role of pre-procedural CT imaging on catheter ablation in patients with atrial fibrillation: procedural outcomes and radiological exposure. *J Interv Card Electrophysiol* 2020:1–8.
5. Kirchoff P, Benussi S, Kotecha D, Ahlsson A, Atar D, Casadei B, Castella M, Diener HC, Heidbuchel H, Hendriks J, Hindricks G, Manolis AS, Oldgren J, Popescu BA, Schotten U, Van-Putte B, Vardas P, Agewall S, Camm J, Baron Esquivias G, Budts W, Carerj S, Casselman F, Coca A, De Caterina R, Deftereos S, Dobrev D, Ferro JM, Filippatos G, Fitzsimons D, Gorenek B, Guenoun M, Hohnloser SH, Kolh P, Lip GY, Manolis A, McMurray J, Ponikowski P, Rosenhek R, Ruschitzka F, Savelieva I, Sharma S, Suwalski P, Tamargo JL, Taylor CJ, Van Gelder IC, Voors AA, Windecker S, Zamorano JL, Zeppenfeld K. 2016 ESC guidelines for the management of atrial fibrillation developed in collaboration with EACTS. *Europace* 2016;18:1609–1678.
- <https://doi.org/10.1016/j.amjcard.2020.07.002>